Table 3 Frequency and incidence of events in the population with co-treatment with antiplatelets (n = 3573)
Risk at 5 years | ||||||
|---|---|---|---|---|---|---|
Outcomes | N | (%) | CI95% | HR | CI95% | p valuea |
Gastrointestinal haemorrhage | ||||||
Cilostazol | 15 | 0.8 | 0.4–1.3 | 0.67 | 0.3–1.3 | 0.232 |
Pentoxifylline | 22 | 1.2 | 0.7–1.8 | |||
Cerebral haemorrhage | ||||||
Cilostazol | 14 | 0.8 | 0.4–1.2 | 1.23 | 0.6–2.7 | 0.604 |
Pentoxifylline | 13 | 0.7 | 0.3–1.1 | |||
Other haemorrhages | ||||||
Cilostazol | 55 | 3.1 | 2.3–3.9 | 0.65 | 0.5–0.9 | 0.014 |
Pentoxifylline | 85 | 4.8 | 3.8–5.8 | |||
Any haemorrhage | ||||||
Cilostazol | 69 | 3.8 | 3.0–4.7 | 0.72 | 0.5–1.0 | 0.040 |
Pentoxifylline | 98 | 5.5 | 4.5–6.6 | |||
CAD | ||||||
Cilostazol | 224 | 12.5 | 10.9–14.0 | 0.93 | 0.8–1.1 | 0.427 |
Pentoxifylline | 237 | 13.3 | 11.8–14.9 | |||
Stroke | ||||||
Cilostazol | 103 | 5.7 | 4.7–6.8 | 0.83 | 0.6–1.1 | 0.180 |
Pentoxifylline | 121 | 6.8 | 5.6–8.0 | |||
AF | ||||||
Cilostazol | 122 | 6.8 | 5.6–8.0 | 1.0 | 0.8–1.3 | 0.999 |
Pentoxifylline | 120 | 6.8 | 5.6–7.9 | |||
Other arrhythmias | ||||||
Cilostazol | 61 | 3.4 | 2.6–4.2 | 1.42 | 1.0–2.1 | 0.082 |
Pentoxifylline | 42 | 2.4 | 1.7–3.1 | |||